Non-invasive, continuous oral delivery of solid levodopa-carbidopa for management of Parkinson's disease.

Autor: Murch WL; synAgile Corporation, Jackson, WY, 83001, USA. murch.william@gmail.com., Spiridigliozzi J; synAgile Corporation, Jackson, WY, 83001, USA., Heller A; synAgile Corporation, Jackson, WY, 83001, USA., Heller E; synAgile Corporation, Jackson, WY, 83001, USA. eheller01@gmail.com.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Nov 05; Vol. 14 (1), pp. 26826. Date of Electronic Publication: 2024 Nov 05.
DOI: 10.1038/s41598-024-78145-4
Abstrakt: When short plasma half-life drugs act only briefly, they require frequent or continuous administration. We report the engineering of a non-invasive oral drug delivery system for long-term, continuous administration of these drugs. Their non-invasive, long-term, continuous administration at daily doses exceeding 100 mg has, for many years, been considered an insurmountable challenge. We show that over 1200 mg/day of 4:1 levodopa-carbidopa (LD-CD) can be non-invasively and continuously extruded when formulated as a semisolid paste, loaded with 63%w/w of the solid drugs. The drug delivery system comprises a reusable orthodontic retainer with a co-molded pocket into which the patient inserts after each meal a new 1 mL propellant-driven, prefilled, disposable, drug delivery extruder. The paste is delivered to the lingual side of the teeth where it is mixed with saliva and swallowed. As reported elsewhere, a 15-day, 16 patient open label clinical trial of the drug delivery system continuously extruding LD-CD paste significantly reduces the variability of the plasma LD concentration and alleviates symptoms of advanced Parkinson's disease (PD) as compared to LD-CD tablets.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje